6418-38-8Relevant articles and documents
19F NMR study on the biodegradation of fluorophenols by various Rhodococcus species
Bondar, Vladimir S.,Boersma, Marelle G.,Golovlev, Eugene L.,Vervoort, Jacques,Van Berkel, Willem J.H.,Finkelstein, Zoya I.,Solyanikova, Inna P.,Golovleva, Ludmila A.,Rietjens, Ivonne M.C.M.
, p. 475 - 486 (1998)
Of all NMR observable isotopes 19F is the one perhaps most convenient for studies on biodegradation of environmental pollutants. THe reasons underlying this potential of 19F NMR are discussed are illustrated on the basis of a study on the biodegradation of fluorophenols by four Rhodococcus strains. The results indicate marked differences between the biodegradation pathways of fluorophenols among the various Rhodococcus species. This holds not only for the level and nature of the fluorinated biodegradation pathway intermediates that accumulate, but also for the regioselectivity of the initial hyroxylation step. Several of the Rhodococcus species contain a phenol hydroxylase that catalyses the oxidative defluorination of ortho- fluorinated di- and trifluorophenols. Furthermore it is illustrated how the 19F NMR technique can be used as a tool in the process of identification of an accumulated unknown metabolite, in this case most likely 5- fluoromaleylacetate. Altogether, the 19F NMR technique proved valid to obtain detailed information on the microbial biodegradation pathways of fluorinated organics, but also provide information on the specificity of enzymes generally considered unstable and, for this reason, not much studied so far.
TRICYCLIC INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF
-
Paragraph 00210, (2019/07/13)
The present application relates to compounds of Formula (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.
INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF
-
Paragraph 00275, (2019/08/29)
The present application relates to compounds of Formula I (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.
Synthesis technology of 2,3-difluorophenol
-
Paragraph 0015; 0029; 0031; 0032; 0034; 0035; 0037, (2018/10/11)
The invention relates to a synthesis technology of 2,3-difluorophenol. 1,2,3-trifluoro-benzene is used as a raw material, and 2,3-difluorophenol is prepared through oxyalkylation and dealkylation reactions. The synthesis route is short, the technology operation is simple, special equipment is not needed, the yield reaches 82% or above, and the synthesis technology has good industrial prospects.
A process for the preparation of 2, 3 - difluoro-phenol method (by machine translation)
-
Paragraph 0039; 0041; 0044; 0047, (2018/10/19)
The invention relates to a process for preparing 2, 3 - difluoro of phenol, to 1, 2, 3 - trifluorobenzene as raw materials, the solid super strong alkali catalytic alkoxylated and dealkylating reaction to prepare 2, 3 - difluoro phenol, synthesis route is short, simple process operation, without special equipment, yield up to 94.8% or more, and has excellent industrial prospect. (by machine translation)
N-Substituted 3(10H)-Acridones as Visible-Light, Water-Soluble Photocatalysts: Aerobic Oxidative Hydroxylation of Arylboronic Acids
Xie, Hong-Yan,Han, Li-Shuai,Huang, Shan,Lei, Xiantao,Cheng, Yong,Zhao, Wenfeng,Sun, Hongbin,Wen, Xiaoan,Xu, Qing-Long
, p. 5236 - 5241 (2017/05/24)
We disclosed a novel water-soluble photocatalyst that could promote aerobic oxidative hydroxylation of arylboronic acids to furnish phenols in excellent yields. This transformation uses visible-light irradiation under environmentally friendly conditions, that is, water-soluble catalyst, metal-free, green oxidant, room temperature.
TREATMENT OF DRY EYE
-
Page/Page column 66, (2014/02/16)
The present disclosure provides a method of treating dry eye by inhibition of Bruton's tyrosine kinase (hereinafter "BTK") inhibitors, pharmaceutical formulations comprising the same, and processes for preparing such compounds.
Tyrosine kinase inhibitors
-
Page/Page column 215, (2014/03/26)
The present disclosure provides compounds such as pyrazolpyrimidine compounds, and pharmaceutically acceptable salts thereof, that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, TEC, BTK, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.
Purinone Derivatives as Tyrosine Kinase Inhibitors
-
Paragraph 0206, (2014/05/25)
The present disclosure provides compounds and pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, TEC, BTK, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as autoimmune diseases, cancer and inflammatory diseases. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.
REVERSIBLE COVALENT PYRROLO- OR PYRAZOLOPYRIMIDINES USEFUL FOR THE TREATMENT CANCER AND AUTOIMMUNE DISEASES
-
Page/Page column 174, (2014/01/09)
Oral pharmaceutical formulations comprising reversible covalent compounds having a Michael acceptor moiety, a process of their production, and use of these formulations for the treatment of diseases treatable by such compounds such as cancer and autoimmune diseases.
